Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 2Phase NA 1Phase 2 1Phase 1 1

Status

Unknown 4Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 7Observational 1

Sponsor

Cancer Type

Thoracic 7

Conditions

Carcinoma, Non-Small-Cell Lung 128Lung Neoplasms 49Breast Neoplasms 24Head and Neck Neoplasms 21Adenocarcinoma of Lung 18Brain Neoplasms 15Neoplasms 14Adenocarcinoma, Bronchiolo-Alveolar 11Squamous Cell Carcinoma of Head and Neck 10Glioblastoma 9Esophageal Neoplasms 9Colorectal Neoplasms 9Rectal Neoplasms 7Prostatic Neoplasms 7Neoplasm Metastasis 7NSCLC 7Gliosarcoma 7Colonic Neoplasms 7Adenocarcinoma Of Esophagus 7Ovarian Neoplasms 5Esophageal Squamous Cell Carcinoma 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Renal Cell 4Carcinoma 4Unspecified Adult Solid Tumor, Protocol Specific 3Skin Neoplasms 3Respiratory Tract Diseases 3Kidney Neoplasms 3

Interventions

Pemetrexed 14Carboplatin 13osimertinib 10Drug Therapy 9aflutinib 8Gefitinib 7Radiotherapy 6Docetaxel 6Cisplatin 6anlotinib 5Radiosurgery 5Paclitaxel 5pembrolizumab 4Vinorelbine 4Gemcitabine 4tislelizumab 3icotinib 3apatinib 3HM781-36B 3Erlotinib Hydrochloride 3toripalimab 2spartalizumab 2rezivertinib 2camrelizumab 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2Immune Checkpoint Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Interventional × NSCLC × Gefitinib × Clear all
NCT03866499 2024-08-07

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

Beta Pharma, Inc.

Phase 3 Active not recruiting
369 enrolled
Thoracic

NSCLC

NCT04390984 2021-01-11

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
22 enrolled
Thoracic

NSCLC

NCT02976116 2019-11-15

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Hutchmed

Phase 2 Completed
50 enrolled
Thoracic

NSCLC

NCT04007835 2019-07-05

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Guangdong Association of Clinical Trials

Phase NA Unknown
120 enrolled
Thoracic

NSCLC

NCT03656393 2018-09-04

RCTACSCNSCLC

Shenzhen People's Hospital

Phase 3 Unknown
48 enrolled
Thoracic

NSCLC

NCT00259064 2016-06-02

INSTEP

AstraZeneca

Phase 2/3 Completed
216 enrolled
Thoracic

NSCLC

NCT02387086 2015-03-12

Gefitinib Combined With Thalidomide to Treat NSCLC

Shaanxi Provincial People's Hospital

Phase 2/3 Unknown
380 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡